Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin and FaceStation in Autism
NCT02090829Phase 2Withdrawn
- Sponsor
- University of Minnesota
- Start
- Mar 2014
- Primary completion
- Mar 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oxytocin in Autism Spectrum Disorder (ASD), sponsored by University of Minnesota. Primary endpoint: The Part/Whole Identity Test at 12 days. Planned start Mar 2014; status: withdrawn.
02
Drugs
oxytocin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT02090829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02090829.